These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26967818)

  • 1. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.
    Binder M; Rajkumar SV; Ketterling RP; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
    Blood Cancer J; 2016 Mar; 6(3):e401. PubMed ID: 26967818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience.
    Jung HA; Jang MA; Kim K; Kim SH
    Ann Lab Med; 2018 May; 38(3):196-203. PubMed ID: 29401553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
    Laï JL; Zandecki M; Mary JY; Bernardi F; Izydorczyk V; Flactif M; Morel P; Jouet JP; Bauters F; Facon T
    Blood; 1995 May; 85(9):2490-7. PubMed ID: 7537117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.
    Mlynarcikova M; Balcarkova J; Mickova P; Scudla V; Pika T; Bacovsky J; Minarik J; Janousova E; Jarosova M
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):358-65. PubMed ID: 27052024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities.
    Lim JH; Seo EJ; Park CJ; Jang S; Chi HS; Suh C; Kim H; Kim SR
    Eur J Haematol; 2014 Apr; 92(4):313-20. PubMed ID: 24372944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
    Neukirchen J; Lauseker M; Hildebrandt B; Nolting AC; Kaivers J; Kobbe G; Gattermann N; Haas R; Germing U
    Cancer; 2017 Dec; 123(23):4608-4616. PubMed ID: 28746789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
    Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of cytogenetic abnormalities with gene expression profiles.
    Zhou Y; Zhang Q; Stephens O; Heuck CJ; Tian E; Sawyer JR; Cartron-Mizeracki MA; Qu P; Keller J; Epstein J; Barlogie B; Shaughnessy JD
    Blood; 2012 May; 119(21):e148-50. PubMed ID: 22496154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The significance and current diagnostic options of cytogenetic changes in multiple myeloma].
    Kuglík P; Filková H; Oltová A; Hájek R
    Vnitr Lek; 2006 Nov; 52 Suppl 2():76-8. PubMed ID: 18175433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic evolution in myeloproliferative neoplasms with different molecular abnormalities.
    Kim SY; Koo M; Park Y; Kim H; Choi Q; Song IC; Jo DY; Kim J; Kwon GC; Koo SH
    Blood Cells Mol Dis; 2019 Jul; 77():120-128. PubMed ID: 31059941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.
    Binder M; Rajkumar SV; Ketterling RP; Greipp PT; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
    Blood Cancer J; 2017 Sep; 7(9):e600. PubMed ID: 28862698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
    Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
    Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
    Chan NC; Chan NP
    Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High risk cytogenetic abnormalities in patients with multiple myeloma].
    Legües ME; Morales P; Valenzuela M; Encina A; Martí MJ; Bascuñán C; Cornejo P; Peña C; Undurraga MS
    Rev Med Chil; 2019; 147(1):61-64. PubMed ID: 30848766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
    Hao S; Lin P; Medeiros LJ; Fang L; Carballo-Zarate AA; Konoplev SN; Sargent RL; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Lu X
    Mod Pathol; 2017 Oct; 30(10):1378-1386. PubMed ID: 28664940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
    Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
    Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal fluorescence
    Merz M; Jauch A; Hielscher T; Mai EK; Seckinger A; Hose D; Bertsch U; Neben K; Raab MS; Salwender H; Blau IW; Lindemann HW; Schmidt-Wolf I; Scheid C; Haenel M; Weisel K; Goldschmidt H; Hillengass J
    Haematologica; 2017 Aug; 102(8):1432-1438. PubMed ID: 28495913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
    Baron F; Stevens-Kroef M; Kicinski M; Meloni G; Muus P; Marie JP; Halkes CJM; Thomas X; Vrhovac R; Specchia G; Lefrere F; Sica S; Mancini M; Venditti A; Hagemeijer A; Becker H; Jansen JH; Amadori S; de Witte T; Willemze R; Suciu S
    Ann Hematol; 2018 Oct; 97(10):1785-1795. PubMed ID: 29926156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
    Jacobson J; Barlogie B; Shaughnessy J; Drach J; Tricot G; Fassas A; Zangari M; Giroux D; Crowley J; Hough A; Sawyer J
    Br J Haematol; 2003 Aug; 122(3):430-40. PubMed ID: 12877670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.